Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting ...

Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...

Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...

Fintel reports that on March 7, 2025, Leerink Partners initiated coverage of CorMedix (NasdaqGM:CRMD) with a Outperform ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...

Stock analysts at Leerink Partners started coverage on shares of CorMedix (NASDAQ:CRMD – Get Free Report) in a report ...

Equities researchers at Leerink Partnrs reduced their FY2025 earnings estimates for ICON Public in a research report issued ...

Leerink analyst Faisal Khurshid raised the firm’s price target on Trevi Therapeutics (TRVI) to $11 from $7 and keeps an Outperform rating on ...

Dave Reisinger, Cover Diversified Biopharmaceuticals, Leerink Partners: All righty. Great. Well, welcome, everyone. My name is Dave Reisinger. For those of you who don’t know me, I cover ...

Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida. Dr. Brady’s ...